Safety Rules Limiting Drug Access For Generics Firms

The US Federal Trade Commission has expressed concerns over generic drugmakers' access to bulk supplies of certain drugs which are part of federal drug safety programs. According to the Wall Street Journal, GlaxoSmithKline (GSK), Celgene, Novartis and Bayer are among patented drugmakers which are requesting that generic drugmakers obtain additional authorisation to purchase certain drugs which have added restrictions. The FTC has taken special note of the incident, with Chairman Jon Leibowitz stating that drug safety should not be used as a tool to delay generic competition.

To read the full article, please choose one of the following options: